Kymera Investor Day Presentation Deck

Expanding Druggable Proteome with Targeted Protein Degradation All therapeutic modalities to date only drug up to 20% of proteome KYMERA ©2021 KYMERA THERAPEUTICS, INC. Undrugged Opportunity Drugged C Traditional Small Molecule Antibody KYMERA R&D DAY - December 16th, 2021 #DOD Antisense N TIT Cell/Gene Therapy RNAi Kymera is expanding the drugged proteome with Targeted Protein Degradation (TPD) PAGE 6

View entire presentation